23:15 , Jul 15, 2019 |  BC Extra  |  Company News

Management tracks: GSK, Orphazyme, Kymera and more

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to confirm news reports stating it will appoint Jonathan Symonds as chairman to succeed Philip Hampton, who has served in the role since 2015. The Financial Times and Bloomberg, citing...
00:47 , Jun 18, 2019 |  BC Extra  |  Company News

Latest twist in uniQure’s tale: possible sale

Five years after returning to the public markets, uniQure may be on the block. While the Dutch gene therapy play declined to comment on a Bloomberg report citing undisclosed sources that the biotech was exploring...
22:05 , May 21, 2019 |  BC Extra  |  Politics & Policy

SCOTUS decision a boon to biopharmas in failure-to-warn cases

A U.S. Supreme Court decision that remands Merck v. Albrecht back to the Court of Appeals for the Third Circuit for a judge to make a final ruling will help drug companies avoid unpredictable jury...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
23:44 , Apr 26, 2019 |  BC Extra  |  Company News

Soriot sees progress in U.S.-China IP debate

AstraZeneca CEO Pascal Soriot said China is making progress on protecting biopharma IP, as the pharma reported 1Q19 earnings that saw a 28% increase year-over-year in sales in the country. "Everything we've seen happening over...
13:53 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting bacterial RelA to enhance isoniazid sensitivity in tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Cell culture and mouse studies suggest inhibiting M. tuberculosis RelA could help treat chronic-phase tuberculosis (TB), which is resistant to the generic antimalarial isoniazid. In an M. tuberculosis culture-based...
14:25 , Feb 22, 2019 |  BC Extra  |  Politics & Policy

FDA rebuts allegations that imported generics are unsafe

FDA punched back Friday against news media stories that accused the agency of lax oversight of generic drugs manufactured in India and China. In a statement , FDA Commissioner Scott Gottlieb and Center for Drug...
21:37 , Feb 14, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2019

New Therapeutic Targets and Biomarkers: January 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January. Therapeutic targets are defined as any protein, gene or other molecule...
00:06 , Jan 23, 2019 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays An assay for detecting P. falciparum PSSP17 in saliva could help rapidly diagnose clinical and subclinical P. falciparum infection at the point of care. The assay comprises mixing saliva samples with two...
00:04 , Dec 15, 2018 |  BC Extra  |  Politics & Policy

Firdapse re-catalyzes pricing debate

A decision by Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) to charge $375,000 a year for Firdapse amifampridine phosphate, a drug that was previously available for free, has re-catalyzed debate about the U.S. government’s drug exclusivity policies. The...